Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IGC Pharma (IGC) Long-Term Investments (2016 - 2025)

IGC Pharma (IGC) has disclosed Long-Term Investments for 11 consecutive years, with $11000.0 as the latest value for Q4 2021.

  • On a quarterly basis, Long-Term Investments changed N/A to $11000.0 in Q4 2021 year-over-year; TTM through Dec 2021 was $11000.0, a N/A change, with the full-year FY2019 number at $794000.0, down 0.63% from a year prior.
  • Long-Term Investments was $11000.0 for Q4 2021 at IGC Pharma, roughly flat from $11000.0 in the prior quarter.
  • In the past five years, Long-Term Investments ranged from a high of $6.0 million in Q4 2017 to a low of $11000.0 in Q3 2021.
  • A 5-year average of $1.1 million and a median of $794000.0 in 2018 define the central range for Long-Term Investments.
  • Peak YoY movement for Long-Term Investments: increased 3.36% in 2018, then crashed 95.79% in 2021.
  • IGC Pharma's Long-Term Investments stood at $6.0 million in 2017, then tumbled by 86.8% to $794000.0 in 2018, then changed by 0.0% to $794000.0 in 2019, then crashed by 67.13% to $261000.0 in 2020, then plummeted by 95.79% to $11000.0 in 2021.
  • Per Business Quant, the three most recent readings for IGC's Long-Term Investments are $11000.0 (Q4 2021), $11000.0 (Q3 2021), and $261000.0 (Q3 2020).